Board Change Update

Diaceutics PLC

29 October 2024

 

Diaceutics PLC - Board Change Update

Belfast and London, 29 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces that following the announcement on 1 October 2024 and completion of the usual Nominated Adviser due diligence checks, Cheryl MacDiarmid is confirmed as having joined the board as a Non-Executive Director.

The following information is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies:

Additional information with regard to Cheryl MacDiarmid:

Cherly MacDiarmid (née Gaskin), age 56, is currently or has been a director of the following companies within the past five years:

Current Directorships	Former Directorships
Allergy Therapeutics Plc
	Phivco UK Limited
	ViiV Healthcare UK (NO.6) Limited
	ViiV Healthcare UK (NO.3) Limited
	ViiV Healthcare UK (NO.5) Limited
	ViiV Healthcare Trading Services UK Limited
	ViiV Healthcare UK (NO.4) Limited
	ViiV Healthcare Overseas Limited
	ViiV Healthcare UK (NO.7) Limited
	ViiV Healthcare Finance Limited
	ViiV Healthcare UK Limited
	Phivco UK II Limited

Enquiries: Diaceutics PLC
Ryan Keeling, Chief Executive Officer  Nick Roberts, Chief Financial Officer	Tel: [phone] [e-mail]
Canaccord Genuity Limited (Nomad & Broker)	Tel: [phone]
Simon Bridges, Andrew Potts, Harry Rees
Alma Strategic Communications	Tel: [phone]
Caroline Forde, Kinvara Verdon	[e-mail]

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

 

END